After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
Pharmaceutical giant Pfizer on Tuesday beat Wall Street analysts' third-quarter earnings expectations but fell short on revenue and narrowed its full-year forecast.
Shares of Pfizer fell about 1 percent.
Here's what the company reported compared with what Wall Street was expecting, based on a survey of analysts by Refinitiv:
Pfizer reported third-quarter net income of $4.11 billion, or 69 cents per share, up from $2.84 billion, or 47 cents per share a year earlier. Excluding items, Pfizer earned 78 per share, more than the 75 cents per share expected by analysts surveyed by Refinitiv.
Net sales rose 1 percent to $13.3 billion, shy of the $13.53 billion analysts had expected.
Innovative health revenue increased 4 percent to $8.47 billion, boosted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside of the U.S., among others. Essential health revenue fell 4 percent to $4.38 billion, with generic versions of Viagra entering the market.
For the full year, Pfizer narrowed its revenue forecast to between $53 billion and $53.7 billion from the previously guided $53 billion to $55 billion. For adjusted earnings per share, Pfizer expects $2.98 to $3.02 from a previous estimate of $2.95 to $3.05.
Pfizer attributed the revenue changes to shortages of its Hospira Sterile Injectable Pharmaceuticals product in the U.S. and weakening currency in some emerging markets and the euro starting this summer.
Earlier this month, Pfizer announced CEO Ian Read will retire and Albert Bourla will take over in January.
"Albert's extensive knowledge of our business, firm grasp of the issues, and deep caring for patients will help Pfizer continue to build on the outstanding foundation we have put in place," Read said in a statement Tuesday.
"I am confident that he is implementing a structure and building a leadership team that will maximize the company's growth opportunities."
Pfizer said it bought back $1.1 billion of its shares in the quarter, bringing its 2018 total to $9 billion. It expects to repurchase about $12 billion this year.
Incoming CEO Bourla told Wall Street analysts that Pfizer doesn't see the need for any large-scale mergers or acquisitions right now as it focuses on its pipeline.